Mogamulizumab Q4week Dosing in Participants With R/R CTCL
← catalyst calendarSponsored by Kyowa Kirin, Inc. (industry) · 4151.T — their whole pipeline →.
Phase
Phase 2
Status
Unknown status
Study type
Interventional
Design
Na · None · Treatment
Enrollment
34actual
Sites
16
Countries
France, Italy, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-08-16 | actual | When the study began enrolling |
| Primary completion | May 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2021-02-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-04-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cutaneous T-Cell Lymphoma, Relapsed
- Cutaneous T-Cell Lymphoma Refractory
Intervention
- Drug: Mogamulizumab — also filed as 0761, KW0761, Poteligeo
Primary outcome
what the primary-completion date above is the date OFNumber, percentage and severity of treatment emergent adverse events
measured From date of consent, at every treatment and follow up visit, up to 27 months
Permalink · 4151.T's whole pipeline · Catalyst calendar · Every registered study · What changed